Novo, Lilly weight-loss drugs should be first option obesity treatments, European doctors (...)
Semaglutide, the active ingredient in Novo's Wegovy and Ozempic, and tirzepatide, sold as Zepbound and Mounjaro by Lilly, are so effective that they should be the first choice in almost all cases when substantial weight loss is necessary, according to a new guideline from the European (...)
Site référencé: The Economic Times
The Economic Times
Axis Bank reassessing plan to sell stake in Axis Finance
1er/10/2025
Unlisted market faces reality check as major IPOs price below grey market levels
1er/10/2025
Sebi extends timeline to roll out algo trading for retail investors
30/09/2025
India Inc’s proportion of rating upgrades to downgrades rises 2.56x in H1FY26 : CareEdge
30/09/2025
Tougher rules on intraday positions to hit F&O traders from tomorrow
30/09/2025
World's big cities see 26% rise in extreme hot days : Study
30/09/2025
